A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Czechia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Czechia23 clinical trials in Chocen, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in CzechiaKlinickeTesty.cz(opens in a new tab)
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
Czechia
CzechiaThe busiest research cities in the country
What the registry says about research in the country
Innovative studies focusing on preventive treatments for various types of migraines, including menstrual, episodic, and chronic forms. Research explores new therapeutic approaches using medications like atogepant and Dysport®.
Multiple comparative studies evaluating treatment effectiveness and patient tolerability.
Comprehensive research into neurodegenerative conditions, particularly focusing on Alzheimer's Disease and Parkinson's Disease. Studies include evaluation of novel therapeutic compounds for disease management.
Trials aim to assess both short and long-term treatment efficacy and safety profiles.
Advanced research in multiple sclerosis and chronic pain management, including studies on innovative treatments for relapsing-remitting MS and chronic back pain conditions.
Focus on developing alternative treatment options and improving patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.